AU2002245379B2 - Prediction of wound healing by urinary nitrate assay - Google Patents

Prediction of wound healing by urinary nitrate assay Download PDF

Info

Publication number
AU2002245379B2
AU2002245379B2 AU2002245379A AU2002245379A AU2002245379B2 AU 2002245379 B2 AU2002245379 B2 AU 2002245379B2 AU 2002245379 A AU2002245379 A AU 2002245379A AU 2002245379 A AU2002245379 A AU 2002245379A AU 2002245379 B2 AU2002245379 B2 AU 2002245379B2
Authority
AU
Australia
Prior art keywords
wound
nitric oxide
subject
level
threshold value
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2002245379A
Other languages
English (en)
Other versions
AU2002245379A1 (en
Inventor
Joseph V. Boykin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2002245379A1 publication Critical patent/AU2002245379A1/en
Application granted granted Critical
Publication of AU2002245379B2 publication Critical patent/AU2002245379B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/795—Porphyrin- or corrin-ring-containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90245—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2002245379A 2001-02-06 2002-02-05 Prediction of wound healing by urinary nitrate assay Expired AU2002245379B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/776,926 US6436366B2 (en) 1999-03-19 2001-02-06 Prediction of wound healing by urinary nitrate assay
US09/776,926 2001-02-06
PCT/US2002/003204 WO2002063308A2 (en) 2001-02-06 2002-02-05 Prediction of wound healing by urinary nitrate assay

Publications (2)

Publication Number Publication Date
AU2002245379A1 AU2002245379A1 (en) 2003-02-13
AU2002245379B2 true AU2002245379B2 (en) 2007-09-06

Family

ID=25108752

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002245379A Expired AU2002245379B2 (en) 2001-02-06 2002-02-05 Prediction of wound healing by urinary nitrate assay

Country Status (10)

Country Link
US (1) US6436366B2 (enExample)
EP (1) EP1360508B1 (enExample)
JP (1) JP2004532389A (enExample)
AT (1) ATE485523T1 (enExample)
AU (1) AU2002245379B2 (enExample)
CA (1) CA2436465A1 (enExample)
DE (1) DE60238032D1 (enExample)
ES (1) ES2354868T3 (enExample)
MX (1) MXPA03007018A (enExample)
WO (1) WO2002063308A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030134332A1 (en) * 2001-11-28 2003-07-17 Boykin Joseph V. Diagnosis of endothelial dysfunction by nitric oxide bioactivity index
WO2004046155A2 (en) * 2002-11-20 2004-06-03 Boykin Jr Joseph V Predicting outcome of hyperbaric oxygen therapy treatment with nitric oxide bioavailability
US8303995B1 (en) 2008-06-13 2012-11-06 Board Of Regents, The University Of Texas System Nitrite formulations and their use as nitric oxide prodrugs
CA2844759A1 (en) * 2011-08-11 2013-02-14 Nathan S. Bryan Method of measuring and monitoring in vivo nitrite levels
BR112014003414B1 (pt) 2011-08-17 2021-09-21 Board Of Regents, The University Of Texas System Composição e sistema de entrega oral para aumento de níveis fisiológicos e terapêuticos de óxido nítrico
CA2923045C (en) * 2013-09-04 2021-10-19 Microbaric Oxygen Systems, Llc Hyperoxic therapy systems, methods and apparatus
US9492374B2 (en) 2015-03-25 2016-11-15 Jose Rafael Salinas Andrade Composition and method for treatment of ulcers

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000057190A2 (en) * 1999-03-19 2000-09-28 Boykin Joseph V Jr Prediction of diabetes impaired wound healing

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000057190A2 (en) * 1999-03-19 2000-09-28 Boykin Joseph V Jr Prediction of diabetes impaired wound healing

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ABD-EL ALEEM SEHAM A et al. Journal of Pathology, vol 191 (4), pg. 434-442, 2000. *
JUDE EDWARD B et al. Wound Repair and Regeneration, vol 9 (5), pg. 353-359, 2001. *

Also Published As

Publication number Publication date
US6436366B2 (en) 2002-08-20
WO2002063308A3 (en) 2002-11-21
ES2354868T3 (es) 2011-03-18
DE60238032D1 (de) 2010-12-02
CA2436465A1 (en) 2002-08-15
MXPA03007018A (es) 2004-10-15
EP1360508A2 (en) 2003-11-12
EP1360508B1 (en) 2010-10-20
US20010047035A1 (en) 2001-11-29
ATE485523T1 (de) 2010-11-15
WO2002063308A2 (en) 2002-08-15
JP2004532389A (ja) 2004-10-21

Similar Documents

Publication Publication Date Title
EP1163528B1 (en) Prediction of diabetes impaired wound healing
US20030134332A1 (en) Diagnosis of endothelial dysfunction by nitric oxide bioactivity index
Peppa et al. Glycoxidation and inflammation in renal failure patients
Mori et al. Effect of eicosapentaenoic acid and docosahexaenoic acid on oxidative stress and inflammatory markers in treated-hypertensive type 2 diabetic subjects
Duan et al. Exposure to phthalates in patients with diabetes and its association with oxidative stress, adiponectin, and inflammatory cytokines
Wang et al. Relations between plasma asymmetric dimethylarginine (ADMA) and risk factors for coronary disease
Salaspuro Use of enzymes for the diagnosis of alcohol-related organ damage
Mojiminiyi et al. Association of C-reactive protein with coronary heart disease risk factors in patients with type 2 diabetes mellitus
Steven et al. CD40L controls obesity-associated vascular inflammation, oxidative stress, and endothelial dysfunction in high fat diet-treated and db/db mice
Andersen et al. Remission of nephrotic syndrome diminishes urinary plasmin content and abolishes activation of ENaC
Škrha et al. Insulin action and fibrinolysis influenced by vitamin E in obese type 2 diabetes mellitus
Šebeková et al. Effects of ramipril in nondiabetic nephropathy: improved parameters of oxidatives stress and potential modulation of advanced glycation end products
Boykin Jr Wound nitric oxide bioactivity: a promising diagnostic indicator for diabetic foot ulcer management
AU2002245379B2 (en) Prediction of wound healing by urinary nitrate assay
Yanagawa et al. Effect of antidiabetic medications on microalbuminuria in patients with type 2 diabetes
Singh et al. Increased concentrations of lipoprotein (a), circadian rhythms and metabolic reactions evoked by acute myocardial infarction, associated with acute reactions in relation to large breakfasts
Wigg et al. Early vitamin E supplementation attenuates diabetes-associated vascular dysfunction and the rise in protein kinase C-β in mesenteric artery and ameliorates wall stiffness in femoral artery of Wistar rats
AU2002245379A1 (en) Prediction of wound healing by urinary nitrate assay
DiSilvestro et al. Plasma diamine oxidase activities in renal dialysis patients, a human with spontaneous copper deficiency and marginally copper deficient rats
Seghieri et al. Plasma and platelet ascorbate pools and lipid peroxidation in insulin‐dependent diabetes mellitus
Costacou et al. Oxidative stress and response in relation to coronary artery disease in type 1 diabetes
US20040112375A1 (en) Predicting outcome of hyperbaric oxygen therapy treatment with nitric oxide bioavailability
Przygodzki et al. 1-methylnicotinamide effects on the selected markers of endothelial function, inflammation and haemostasis in diabetic rats
Virgolici et al. Correlations between dysglycemia, markers of oxidative stress and inflammation in diabetic foot patients
Nash Long-term Systemic Inflammation and Age-related Hearing Impairment

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired